Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07714291

CPHARM - CRC Study

Colorectal cancer is one of the most common cancers in Malaysia and worldwide. Although it can often be prevented or treated successfully when detected early, many people in Malaysia are diagnosed at an advanced stage. Screening tests, such as the immunochemical faecal occult blood test (iFOBT), can help detect early signs of colorectal cancer; however, participation in screening remains low.

Community pharmacies are easily accessible healthcare settings where people frequently seek health advice. Pharmacists may play an important role in improving awareness and encouraging colorectal cancer screening by providing education and support. However, more information is needed to understand how people perceive and respond to pharmacy-based colorectal cancer screening.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

50 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 50 to 75 years
  • Visiting participating community pharmacies during the study period
  • Able to provide informed consent
  • Willing to complete the study questionnaire
  • Willing to provide consent for follow-up assessment of: iFOBT provision, iFOBT testing completion, iFOBT results

Exclusion criteria

  • Previous diagnosis of colorectal cancer
  • History of colonoscopy within the recommended screening interval (within past 1 year)
  • Currently experiencing symptoms suggestive of colorectal cancer
  • Having a first-degree relative diagnosed with colorectal cancer

Treatment and study plan

Health awareness campaign

Behavioral

Campaign Components The one-day Ribbon of Hope campaign will be implemented at each intervention pharmacy to promote colorectal cancer awareness and screening uptake. The campaign consists of educational materials and one-on-one education about colorectal cancer.

Primary outcomes

  1. Beliefs and perceptions toward colorectal cancer and iFOBT screening

    Time frame: From enrollment to the 8th week follow-up.

    Beliefs and perceptions toward colorectal cancer and iFOBT screening, measured using the Champion Health Belief Model Scale - Colorectal Cancer - Malay (CHBMS-CRC-M) subscales of perceived susceptibility, perceived benefits, and perceived barriers, between customers from pharmacies with and without the one-day awareness campaign.

    Each item is rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree). Domain scores will be calculated by summing (or averaging) the items within each domain, with higher scores indicating greater perceived susceptibility, benefits or barriers.

Secondary outcomes

  1. Proportion of participants who were willing to accept and perform iFOBT, report iFOBT results, and follow-up if needed.

    Time frame: From enrollment to the 8th week of follow-up

Study contacts

Contact information is provided by the study sponsor or research team.

Chee Tao Chang

CONTACT

[email protected]

Yen Jun Wong

CONTACT

[email protected]

60355146286

Sponsors and collaborators

Lead sponsor

Monash University Malaysia

Other

Registry information

Official study title

Community Pharmacy-Based Health-Seeking Behaviour and Colorectal Cancer Screening Uptake Among Malaysian Adults

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 20, 2026
Registry last updated
Jul 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.